The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBodycote Regulatory News (BOY)

Share Price Information for Bodycote (BOY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 747.00
Bid: 744.00
Ask: 748.00
Change: 7.00 (0.95%)
Spread: 4.00 (0.538%)
Open: 740.00
High: 748.00
Low: 739.00
Prev. Close: 740.00
BOY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

22 Nov 2023 07:00

RNS Number : 1964U
Bodycote PLC
22 November 2023
 

 

 

Wednesday, 22 November 2023

 

 

Bodycote plc

 

On track to meet full year expectations

 

Bodycote, the world's leading provider of heat treatment and specialist thermal processing services, issues a trading update covering the four month period from 1 July to 31 October 2023 ("the period").

 

Trading

Bodycote delivered year-to-date revenue of £677m, representing growth of 10% versus the prior year, which is up 6% excluding energy related surcharges and at constant currency. Operating margins have increased in line with our expectations.

 

In the four month period, the Group delivered revenue of £257m, up 4% year-on-year at constant currency on both a pre and post surcharge basis.

 

The following commentary reflects constant currency growth rates versus the comparable period last year, unless stated otherwise.

 

ADE revenues were £116m, up 10% (8% excluding surcharges). AGI revenues of £140m were down 1% year-on-year but up 1% when the effect of declining surcharges are excluded.

 

The Specialist Technologies portion of the divisions achieved revenue growth of 8% both before and after the impact of surcharges. Growth continued to outperform Classical Heat Treatment, where revenues rose by 2% pre and post surcharges.

 

Divisional revenues in Emerging Markets declined by 7% (down 6% excluding surcharges), with lower activity in China and Eastern Europe.

 

Market Sectors

 

Aerospace & Defence revenues increased by 13% (10% excluding surcharges), in line with the rate of growth delivered in H1 and led by ongoing growth in Civil Aerospace (up 11% excluding surcharges). This reflected market share gains in Classical Heat Treatment in North America, together with OEM build rate increases and higher aftermarket demand. Defence growth was 6%, excluding surcharges. Industry-wide Aerospace supply chain issues remain, but are progressively improving.

 

Automotive revenues were down 2%, driven by reduced surcharges. Underlying growth was 1% excluding the impact of surcharges. The reduction in growth versus the first half of the year reflected the more modest increases in car and light truck production rates and the UAW strike. Bodycote's penetration of the Electric Vehicle market continues to improve.

 

General Industrial (including Energy) revenues were up 2% (3% excluding the impact of falling surcharges). Bodycote achieved strong growth in both Oil & Gas and Medical subsectors, which constitute 18% of General Industrial revenues. Within the Oil & Gas subsector, the Group's share of the Surface Technology markets in EMEA grew significantly. There were revenue declines in a number of subsectors, including Tooling, Industrial Machinery and Electronics. Geographically, Western European growth was ahead of that in North America.

 

Financial position and liquidity

Net debt, excluding lease liabilities at 31 October was £6.7m, an improvement of £19.9m from 30 June, reflecting good cash flow conversion in the period.

 

The interim dividend of £12.6m was paid on 10 November 2023.

 

The acquisitions of Stack Metallurgical Group and Lake City Heat Treating have not yet completed and are progressing through regulatory clearance processes.

 

Outlook

Reflecting the good progress achieved year-to-date, the Board's expectations for full year 2023 remain unchanged. Looking beyond this year, the Board remains confident in the Group's prospects for continued profitable growth.

 

Trading Update Conference Call

Bodycote will be hosting a conference call for analysts and investors at 8.30am UK GMT today (Wednesday, 22 November 2023).

 

Participants' dial-in number:

UK & Europe: +44 208 609 4318

North America: +1 888 396 8063

 

Participants will be asked for names only; no PIN will be required.

 

For further information, please contact:

 

Bodycote plc

Stephen Harris, Group Chief Executive

Ben Fidler, Chief Financial Officer

Tel: +44 1625 505 300

 

FTI Consulting

Richard Mountain

Susanne Yule

Tel: +44 203 727 1340

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBRBDBCXDDGXB
Date   Source Headline
31st Jan 20244:30 pmPRNTotal Voting Rights
31st Jan 20243:57 pmPRNBodycote plc - Holding(s) in Company
22nd Jan 20247:00 amRNSAcquisition Update and Share Buyback Programme
8th Jan 20244:37 pmPRNHolding(s) in Company
29th Dec 202312:25 pmPRNTotal Voting Rights
8th Dec 20234:40 pmPRNDirector/PDMR Shareholding
30th Nov 20234:30 pmPRNTotal Voting Rights
22nd Nov 20237:00 amRNSTrading Update
10th Nov 202312:08 pmPRNDirector/PDMR Shareholding
9th Nov 20237:00 amRNSDirector Declaration
31st Oct 20234:30 pmPRNTotal Voting Rights
31st Oct 202310:07 amPRNDirector/PDMR Shareholding
18th Oct 20237:00 amRNSGroup Chief Executive Appointment
9th Oct 20237:00 amRNSSpecialist Tech Acquisitions & New HIP Facility
29th Sep 20234:30 pmPRNBodycote plc - Total Voting Rights
31st Aug 20234:30 pmPRNBodycote plc - Total Voting Rights
16th Aug 20232:38 pmPRNDirector/PDMR Shareholding
4th Aug 202310:43 amPRNHolding(s) in Company
31st Jul 20235:00 pmPRNTotal Voting Rights
27th Jul 20237:00 amRNSInterim results for the six months to 30 June 2023
30th Jun 20235:00 pmPRNTotal Voting Rights
31st May 202312:45 pmRNSSenior Independent Director succession
31st May 202312:43 pmRNSResult of AGM
31st May 20237:00 amRNSGroup Chief Executive Succession Process
31st May 20237:00 amRNSTrading Update
28th Apr 20235:02 pmPRNTotal Voting Rights
17th Mar 20237:00 amRNSFull year results for year ended 31 December 2022
16th Mar 20237:00 amRNSRemuneration Committee Chair Succession
18th Nov 20227:00 amRNSTrading Update
31st Oct 20227:00 amRNSAppointment of Chief Financial Officer
29th Jul 20227:00 amRNSInterim results for the six months to 30 June 2022
28th Jun 20229:22 amRNSHolding(s) in Company
31st May 20225:02 pmPRNTotal Voting Rights
27th May 20224:47 pmRNSHolding(s) in Company
27th May 20227:00 amRNSHolding(s) in Company
26th May 20225:11 pmRNSHolding(s) in Company
25th May 20222:41 pmPRNDirector/PDMR Shareholding
25th May 202212:21 pmRNSResult of AGM
25th May 20227:11 amRNSAudit Committee Chair Succession
25th May 20227:00 amRNSTrading Update
13th Apr 202211:00 amPRNHolding(s) in Company
6th Apr 20229:07 amPRNDirector/PDMR Shareholding
4th Apr 20224:16 pmPRNFinal Dividend Payment Date
31st Mar 20225:02 pmPRNTotal Voting Rights
28th Mar 202212:13 pmPRNDirector/PDMR Shareholding
25th Mar 20223:18 pmPRNDirector/PDMR Shareholding
25th Mar 20221:39 pmPRNAnnual Financial Report
25th Mar 20221:12 pmPRNDirector/PDMR Shareholding
15th Mar 20224:53 pmPRNDirector/PDMR Shareholding
14th Mar 20227:00 amRNSFull year results for year ended 31 December 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.